Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.
Blood
; 115(16): 3215-23, 2010 Apr 22.
Article
en En
| MEDLINE
| ID: mdl-20032498
Palabras clave
Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Separation; Combined Modality Therapy; Female; Flow Cytometry; Humans; Immunohistochemistry; Immunotherapy; Lymphoma, Mantle-Cell; MRD; Male; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Polymerase Chain Reaction; Prognosis; RQ-PCR; Radiotherapy; Treatment Outcome; autologous stem cell transplantation; immunochemotherapy; mantle cell lymphoma; methods; minimal residual disease; pathology; therapeutic use; therapy
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Radioterapia
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Linfoma de Células del Manto
/
Inmunoterapia
Tipo de estudio:
Clinical_trials
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Blood
Año:
2010
Tipo del documento:
Article
País de afiliación:
Alemania